Date: 2013-08-06
Type of information: Licensing agreement
Compound: Veregen® ointment (made from the extract of green tea leaves - catechins)
Company: Medigene (Germany) Difa Cooper (Italy - Spain)
Therapeutic area: Infectious diseases - Gynecology - Women's health
Type agreement: licensing
commercialisation
Action mechanism:
Disease: genital warts
Details: * On August 6, 2013. Medigene has announced the conclusion of an exclusive license and supply agreement with Difa Cooper SPA, the Italian subsidiary of the Spanish pharmaceutical company IFC (Industrial Farmaceutica Cantabria), for the supply and commercialization of Veregen® in Italy. After approval Difa Cooper will promote and distribute the drug for the treatment of genital warts.
Veregen®is already being marketed in the USA (by Fougera), in Germany, Austria and Switzerland (by Abbott), in Spain (by Bial), in Serbia (by Pharmanova) as well as in the Netherlands (by Will-Pharma) and approved in further countries. Market approvals and the launch of Veregen® in several other countries are pending in 2013. The marketing authorization application for Italy and the remaining European countries is in preparation. Medigene has entered into several marketing partnerships for Veregen® across Europe, Asia, and America, and is planning to continue this global licensing strategy to further leverage the product\'s market potential.
Financial terms: In addition to a one-time upfront payment, Medigene will also obtain revenues from milestone payments, from the supply of the finished product, as well as double-digit royalties on the future sales of Veregen®.
Latest news:
